SCHEMBL560944

SCHEMBL560944

Cc1c(-c2ccccc2)cc(C(=O)NOc2ccccc2)c(=O)n1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.48
NOTUM Q6P988 1/20 0.47
PLA2G10 O15496 1/20 0.41
GSR P00390 3/20 0.41
TP53 P04637 2/20 0.41
MAPT P10636 1/20 0.41
CYP1A2 P05177 2/20 0.40
KMT2A Q03164 1/20 0.39
TRPV4 Q9HBA0 3/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PPARG P37231 1/20 0.38
CYP3A4 P08684 1/20 0.38
GAA P10253 1/20 0.38
CYP2C19 P33261 1/20 0.38
SCN2B O60939 1/20 0.38
SCN1B Q07699 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31490303 1.00 ELANE (0.48) ELANENOTUMPLA2G10GSRTP53
SCHEMBL11895153 0.85 NOTUM (0.47) ELANENOTUMPLA2G10GSRTP53
SCHEMBL31490345 0.85 NOTUM (0.53) ELANENOTUMPLA2G10GSRMAPT
SCHEMBL560810 0.85 NOTUM (0.61) ELANENOTUMPLA2G10GSRCYP1A2
SCHEMBL5757500 0.84 ELANE (0.58) ELANENOTUMPLA2G10GSRTP53
SCHEMBL561309 0.84 ELANE (0.54) ELANEPPARG
SCHEMBL31490347 0.84 ELANE (0.54) ELANEPPARG
SCHEMBL5445143 0.82 PLA2G10 (0.56) ELANENOTUMPLA2G10GSRTP53
SCHEMBL561192 0.82 CNR1 (0.50) ELANENOTUMALDH1A1PPARG
SCHEMBL560993 0.82 CNR2 (0.52) ELANENOTUMNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501784-B2 2-pyridone derivatives as neutrophil elastase inhibitors and their use ASTRAZENECA AB (SE) 2013-08-06 US claimed
EP-1663973-B3 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE ASTRAZENECA AB (SE) 2019-09-25 EP disclosed
EP-1663973-B1 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE ASTRAZENECA AB (SE) 2013-12-25 EP disclosed
US-8501784-B2 2-pyridone derivatives as neutrophil elastase inhibitors and their use ASTRAZENECA AB (SE) 2013-08-06 US disclosed
US-20120035157-A1 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE ASTRAZENECA AB (SE) 2012-02-09 US disclosed
US-8063073-B2 2-pyridone derivatives as neutrophil elastase inhibitors and their use ASTRAZENECA AB (SE) 2011-11-22 US disclosed
US-20070203129-A1 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use ASTRAZENECA AB (SE) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035157-A1 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE SERPINB1, ELANE, SERPINE1 ELANE 2/4885NOTUM 3528/4885PLA2G10 253/4885
US-20070203129-A1 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use SERPINB1, ELANE, SERPINE1 ELANE 2/4885NOTUM 3343/4885PLA2G10 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.